Table 1 Results of the susceptibility testing of Staphylococcus hominis
Antibiotics | POD 11 | POD 14 | POD 19 | POD 27 | POD 35 | POD 44 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
MIC | Interpretation | MIC | Interpretation | MIC | Interpretation | MIC | Interpretation | MIC | Interpretation | MIC | Interpretation | |
Cefazolin sodium | < 2 | S | < 2 | S | < 2 | S | < 2 | S | < 2 | S | < 2 | S |
Ampicillin/sulbactam | < 8 | S | < 8 | S | < 8 | S | < 8 | S | < 8 | S | < 8 | S |
Amoxicillin/clavulanate | < 2 | S | < 2 | S | < 2 | S | < 2 | S | < 2 | S | < 2 | S |
Levofloxacin hydrate | < 0.5 | S | < 0.5 | S | < 0.5 | S | < 0.5 | S | < 0.5 | S | < 0.5 | S |
Meropenem hydrate | < 1 | S | < 1 | S | < 1 | S | < 1 | S | < 1 | S | < 1 | S |
Daptomycin | < 0.25 | S | < 0.25 | S | < 0.25 | S | < 0.25 | S | < 0.25 | S | < 0.25 | S |
Linezolid | < 1 | S | < 1 | S | < 1 | S | < 1 | S | < 1 | S | < 1 | S |
Vancomycin hydrochloride | < 0.5 | S | < 0.5 | S | < 0.5 | S | < 0.5 | S | 1 | S | < 0.5 | S |
Clindamycin phosphate | < 0.25 | S | < 0.25 | S | < 0.25 | S | < 0.25 | S | < 0.25 | S | < 0.25 | S |